Selecting from CAR T-Cell Therapies in DLBCL – OncLive
OncLive |
Selecting from CAR T-Cell Therapies in DLBCL
OncLive Stephen J. Schuster, MD: Axi-cel (Yescarta) is the first CAR T cell product that was approved for the treatment of diffuse large B-cell lymphoma in November of 2017. Most of my experience has been with what is now called Kymriah (tisagenlecleucel). It … |
